Role of non-classical MHC class I molecules in cancer immunosuppression
暂无分享,去创建一个
Grazyna Kochan | David Escors | Karine Breckpot | K. Breckpot | G. Kochan | D. Escors | D. Guerrero-Setas | David Guerrero-Setas | D. Guerrero‐Setas
[1] N. Rouas-Freiss,et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. , 2008, Blood.
[2] H. Orr,et al. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. , 1988, Journal of immunology.
[3] Julia M. Lewis,et al. Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.
[4] D. Geraghty,et al. Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F, and G in Maternal-Placental Immune Recognition 1 , 2003, The Journal of Immunology.
[5] A. Moreau,et al. Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.
[6] A. Hayday,et al. Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.
[7] S. Ferrone,et al. Soluble HLA‐A,‐B,‐C and ‐G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation , 2003, European journal of immunology.
[8] H. Rammensee,et al. Nonclassical HLA-G molecules are classical peptide presenters , 1996, Current Biology.
[9] P. Coulie,et al. Identification of effector‐memory CMV‐specific T lymphocytes that kill CMV‐infected target cells in an HLA‐E‐restricted fashion , 2005, European journal of immunology.
[10] J. Dausset,et al. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. , 2003, Advances in immunology.
[11] A. McMichael,et al. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide , 1998, Current Biology.
[12] H. Orr,et al. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. , 1990, Human immunology.
[13] A. McMichael,et al. The human major histocompatibility complex class Ib molecule HLA‐E binds signal sequence‐derived peptides with primary anchor residues at positions 2 and 9 , 1997, European journal of immunology.
[14] E. Donadi,et al. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. , 2011, Molecular biology and evolution.
[15] A. Merlo,et al. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. , 2000, Human immunology.
[16] D. Geraghty,et al. HLA‐F is a surface marker on activated lymphocytes , 2010, European journal of immunology.
[17] J. Kellermann,et al. Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding. , 1992 .
[18] D. Geraghty,et al. Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.
[19] M. Sarwal,et al. Expression of Soluble HLA-G Identifies Favorable Outcomes in Liver Transplant Recipients , 2010, Transplantation.
[20] E. Carosella,et al. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. , 2006, Transplant immunology.
[21] J. Johnson,et al. Analysis of HLA class Ib gene expression in male gametogenic cells , 1997, European journal of immunology.
[22] Martin A. Cheever,et al. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.
[23] M. Kurrer,et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. , 2001, The American journal of pathology.
[24] J. Michálek,et al. Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. , 2012, Pathology, research and practice.
[25] A. McMichael,et al. Requirement of the Proteasome for the Trimming of Signal Peptide-derived Epitopes Presented by the Nonclassical Major Histocompatibility Complex Class I Molecule HLA-E* , 2003, Journal of Biological Chemistry.
[26] E. Donadi,et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. , 2008, Transplant immunology.
[27] S. Ugurel,et al. Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy , 2001 .
[28] K. Bogunia-Kubik,et al. Clinical Significance of the HLA-E and CD94/NKG2 Interaction , 2011, Archivum Immunologiae et Therapiae Experimentalis.
[29] S. Ugurel,et al. Soluble HLA‐DR is a potent predictive indicator of disease progression in serum from early‐stage melanoma patients , 2002, International journal of cancer.
[30] J. Bell,et al. Functional characterization of HLA‐F and binding of HLA‐F tetramers to ILT2 and ILT4 receptors , 2000, European journal of immunology.
[31] M. Weller,et al. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells , 2012, Journal of Neuroimmunology.
[32] X. Zhang,et al. Alteration of HLA‐F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma , 2013, International journal of cancer.
[33] D. Geraghty,et al. Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. , 2002, Tissue antigens.
[34] J. Dausset,et al. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6—STAT3 signaling pathway , 2008, Proceedings of the National Academy of Sciences.
[35] R. Rizzo,et al. HLA-G expression is a fundamental prerequisite to pregnancy. , 2007, Human immunology.
[36] J. Trapani,et al. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.
[37] Judith E. Cartwright,et al. Soluble HLA-G and control of angiogenesis. , 2007, Journal of reproductive immunology.
[38] E. Carosella,et al. The immunosuppressive molecule HLA-G and its clinical implications , 2012, Critical reviews in clinical laboratory sciences.
[39] L. Chess,et al. Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. , 2001, Journal of immunology.
[40] S. Munro,et al. Selective Export of HLA-F by Its Cytoplasmic Tail1 , 2006, The Journal of Immunology.
[41] E. Jordanova,et al. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival , 2012, Journal of Translational Medicine.
[42] H. Orr,et al. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[43] C. Volteau,et al. HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression , 2012, International journal of cancer.
[44] Kouhei Tsumoto,et al. Efficient Leukocyte Ig-like Receptor Signaling and Crystal Structure of Disulfide-linked HLA-G Dimer* , 2006, Journal of Biological Chemistry.
[45] N. Rouas-Freiss,et al. Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology. , 2005, Autoimmunity reviews.
[46] D. Chan,et al. HLA-G is a potential tumor marker in malignant ascites. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] A. Berrebi,et al. HLA class I/NK cell receptor interaction in early human decidua basalis: possible functional consequences. , 2005, Chemical immunology and allergy.
[48] V. Guiard,et al. © 1999 The Japanese Society for Immunology IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes , 2022 .
[49] H. Orr,et al. Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element , 1990, The Journal of experimental medicine.
[50] Elisa Lo Monaco,et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis , 2011, Journal of Translational Medicine.
[51] L. Chess,et al. Induction of TCR Vβ-Specific CD8+ CTLs by TCR Vβ-Derived Peptides Bound to HLA-E1 , 2001, The Journal of Immunology.
[52] E. Carosella,et al. HLA‐G up‐regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[53] K. Egawa,et al. Detection of anti-HLA-F antibodies in sera from cancer patients. , 2004, Anticancer research.
[54] L. Chess,et al. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. , 2010, The Journal of clinical investigation.
[55] Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding , 2013, Molecular and Cellular Biochemistry.
[56] Judith E. Cartwright,et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. , 2006, Blood.
[57] N. Rouas-Freiss,et al. Modulation of HLA-G Expression in Human Neural Cells after Neurotropic Viral Infections , 2005, Journal of Virology.
[58] Wei Zhang,et al. Tolerization of dendritic cells by HLA‐G , 2005, European journal of immunology.
[59] B. Seliger,et al. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. , 2003, Human immunology.
[60] Shiyong Chen,et al. Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. , 2009, The Journal of infectious diseases.
[61] A. Moreau,et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. , 2007, Blood.
[62] J. Johnson,et al. Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding , 1992, The Journal of experimental medicine.
[63] S. H. van der Burg,et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes , 2011, Proceedings of the National Academy of Sciences.
[64] C. Demanet,et al. Soluble HLA-G in rheumatoid arthritis. , 2006, Human immunology.
[65] K. Thielemans,et al. Lentiviral vectors: a versatile tool to fight cancer. , 2013, Current molecular medicine.
[66] A. Woltman,et al. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. , 1999, Journal of immunology.
[67] L. Lanier,et al. A Signal Peptide Derived from hsp60 Binds HLA-E and Interferes with CD94/NKG2A Recognition , 2002, The Journal of experimental medicine.
[68] S. Ferrone,et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? , 2005, Cancer research.
[69] D. Geraghty,et al. HLA-F Surface Expression on B Cell and Monocyte Cell Lines Is Partially Independent from Tapasin and Completely Independent from TAP1 , 2003, The Journal of Immunology.
[70] E. Carosella,et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. , 2006, Blood.
[71] P. Moreau,et al. Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.
[72] S. Agaugué,et al. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. , 2011, Blood.
[73] D. Furman,et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. , 2008, International journal of oncology.
[74] J. Dausset,et al. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[75] Wenfu Zhou,et al. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. , 2011, Lung cancer.
[76] J. McCluskey,et al. Biology and functions of human leukocyte antigen-G in health and sickness. , 2003, Tissue antigens.
[77] O. Mandelboim,et al. Soluble nonclassical HLA generated by the metalloproteinase pathway. , 2003, Human immunology.
[78] G. Ferrara,et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. , 2000, Human immunology.
[79] Kazuhiro Suzuki,et al. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA‐E through mostly shared but partly distinct sets of HLA‐E residues , 2004, European journal of immunology.
[80] P. J. van den Elsen,et al. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. , 2000, Human immunology.
[81] D. Stolke,et al. Secretion of sHLA-G molecules in malignancies. , 2003, Seminars in cancer biology.
[82] P. A. Peterson,et al. Cell surface expression of HLA‐E: interaction with human β2‐microglobulin and allelic differences , 1999, European journal of immunology.
[83] M. Weller,et al. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. , 2005, Journal of neuropathology and experimental neurology.
[84] P. Le Bouteiller,et al. Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story. , 1996, Research in immunology.
[85] Longmei Zhao,et al. Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization. , 2012, Human immunology.
[86] B. Dréno,et al. Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer , 2011, PloS one.
[87] J. Dausset,et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.